Trelagliptin Succinate

Trelagliptin succinate is primarily applied in the treatment of type 2 diabetes mellitus. Its role as a DPP-4 inhibitor makes it effective in managing blood glucose levels in diabetic patients. Additionally, its ability to improve insulin sensitivity and regulate lipid metabolism positions it as a potential therapeutic agent for obesity-related metabolic disorders.

Trelagliptin succinate exhibits significant biological activity as a DPP-4 inhibitor. Research indicates that it not only improves insulin sensitivity but also regulates adipokine secretion, which is crucial for metabolic health. In vitro studies using 3T3-L1 adipocytes demonstrated that trelagliptin succinate enhances glucose uptake through the activation of glucose transporter type 4 (GLUT4) via the PI3K/AKT signaling pathway. Furthermore, it has been shown to affect gene expression related to insulin signaling, thereby contributing to improved metabolic profiles in diabetic models.

Please email your required order quantity and detailed technical specifications to sales@.
Our sales team will promptly prepare an accurate quotation for your bulk order and provide a comprehensive pricing proposal.

All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.